How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,724 results for

Phosphodiesterase Inhibitor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. The effect of phosphodiesterase-5 inhibitors on uteroplacental and fetal cerebral perfusion in pregnancies with fetal growth restriction: a systematic review and meta-analysis

The effect of phosphodiesterase-5 inhibitors on uteroplacental and fetal cerebral perfusion in pregnancies with fetal growth restriction: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

122. In Chronic Cardiac Decompensation with Reduced Left Ventricular Ejection Fraction, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis Full Text available with Trip Pro

, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis. Preprints 2017, 2017030177 (doi: 10.20944/preprints201703.0177.v1). Copy CANCEL COPY CITATION DETAILS Abstract Background: In patients with pulmonary arterial hypertension, substantial clinical benefits have been reported with the use of phosphodiesterase-5 inhibitors(PDE5i) . Moreover, some studies would have proven useful effects of PDE5i also on the clinical picture (...) In Chronic Cardiac Decompensation with Reduced Left Ventricular Ejection Fraction, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis In Chronic Cardiac Decompensation with Reduced Left Ventricular Ejection Fraction, Phosphodiesterase-5 Inhibition Exerts Significant Effects on some Clinical, Functional and Hemodynamic Outcomes: a Meta-Analysis[v1] | Preprints Share this article with Create alert Email: Submit

2017 MDPI AG

123. Effect of 5-phosphodiesterase inhibitors on sexual function in females: a systematic review and meta-analysis

Effect of 5-phosphodiesterase inhibitors on sexual function in females: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

124. The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses

The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

125. Phosphodiesterase-5 inhibitors in Pregnancy: A systematic review of maternal side effects, obstetric and perinatal outcomes

Phosphodiesterase-5 inhibitors in Pregnancy: A systematic review of maternal side effects, obstetric and perinatal outcomes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

126. Impact of Testosterone Replacement Therapy on patients with hypogonadal unresponsive to phosphodiesterase 5 inhibitors alone: a systematic review and meta-analysis

Impact of Testosterone Replacement Therapy on patients with hypogonadal unresponsive to phosphodiesterase 5 inhibitors alone: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

127. Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO2 Full Text available with Trip Pro

. (2013) Effects of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 309: 1268-1277. 14. Wu X, Y ang T, Zhou Q, Li S, Huang L, et al. (2013) Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 16: 444-453. 15. Garg N, Sharma MK, Sinha N (2006) Role of oral sildenafil in severe (...) Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO2 Effects of Phosphodiesterase Type 5 (PDE-5) Inhibitors in the Management of Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis Pointing on Peak VO 2 Rutahoile WM 1 , David NM 1 , Angela AP 1 , Abdallah ZH 1 , Xiao Li Zhou 2 , Huang Wei 1 and Lei Han 1* 1 The First Affiliated Hospital of Chongqing Medical

2017 Journal of Hypertension: Open Access

128. Role of phosphodiesterase inhibitors in stent related symptoms: a systematic review and meta-analysis

Role of phosphodiesterase inhibitors in stent related symptoms: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

129. The effects of CPAP and phosphodiesterase type 5 inhibitors on erectile function in men with obstructive sleep apnea and erectile dysfunction: a systematic review and meta-analysis

The effects of CPAP and phosphodiesterase type 5 inhibitors on erectile function in men with obstructive sleep apnea and erectile dysfunction: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

130. Efficacy and safety of phosphodiesterase-5 inhibitors for the treatment of erectile dysfunction after rectal excision for cancer and inflammatory bowel disease: systematic review and meta-analysis

Efficacy and safety of phosphodiesterase-5 inhibitors for the treatment of erectile dysfunction after rectal excision for cancer and inflammatory bowel disease: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

131. Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: a systematic review and meta-analysis

Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

132. Efficacy and safety of phosphodiesterase 5 inhibitors in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: systematic review and meta-analysis

Efficacy and safety of phosphodiesterase 5 inhibitors in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

133. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer (Abstract)

Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer The association between phosphodiesterase type 5 inhibitors (PDE5-Is), drugs used in the treatment of erectile dysfunction (ED), and melanoma skin cancer is controversial.To assess whether the use of PDE5-Is is associated with an increased risk of melanoma skin cancer.Using the UK Clinical Practice Research Datalink, we assembled a cohort of men newly diagnosed with ED between 1998 and 2014 and followed until 2015. PDE5-I (...) with basal and squamous cell carcinoma, with an unclear association with numbers of prescriptions and pills received.The use of PDE5-Is was not associated with an overall increased risk of melanoma skin cancer. The increased risks observed in the highest prescription and pill categories require further validation.In this study, the use of phosphodiesterase type 5 inhibitors was not associated with an increased risk of melanoma skin cancer.Copyright © 2016. Published by Elsevier B.V.

2016 EvidenceUpdates

134. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Full Text available with Trip Pro

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents.Patients (N=505) were randomised (1:1:1) to placebo, apremilast 20 mg twice daily, or apremilast 30 mg twice

2016 EvidenceUpdates Controlled trial quality: uncertain

135. Docking and quantitative structure-activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors. Full Text available with Trip Pro

Docking and quantitative structure-activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors. PDE3s belong to the phosphodiesterases family, where the PDE3A isoform is the major subtype in platelets involved in the cAMP regulation pathway of platelet aggregation. PDE3A inhibitors have been designed as potential antiplatelet agents. In this work, a homology model of PDE3A was developed and used to obtain the binding modes (...) of bicyclic heteroaromatic pyridazinones and pyrazolones. Most of the studied compounds adopted similar orientations within the PDE3A active site, establishing hydrogen bonds with catalytic amino acids. Besides, the structure-activity relationship of the studied inhibitors was described by using a field-based 3D-QSAR method. Different structure alignment strategies were employed, including template-based and docking-based alignments. Adequate correlation models were obtained according to internal

2017 PLoS ONE

136. Use of phosphodiesterase inhibitors and prevalence of self-reported glaucoma in the United States. Full Text available with Trip Pro

Use of phosphodiesterase inhibitors and prevalence of self-reported glaucoma in the United States. While decreased ocular blood flow is thought to be a possible contributor to glaucoma pathogenesis, it is unclear what role systemic phosphodiesterase inhibitors (PDEi) play. We performed a cross-sectional study of a nationally representative sample of the U.S. population to investigate the relationship between the most commonly used PDEi, sildenafil and theophylline, and self-reported glaucoma.We

2017 PLoS ONE

137. The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. Full Text available with Trip Pro

The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. Since the degeneration of the nigrostriatal dopaminergic pathway in Parkinson's disease (PD) is associated with the inflammation process and decreased levels of cyclic nucleotides, inhibition of up-regulated cyclic nucleotide phosphodiesterases (PDEs) appears to be a promising therapeutic strategy. We used ibudilast (IBD), a non-selective PDE3,4,10,11 inhibitor, due to the abundant

2017 PLoS ONE

138. Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury. Full Text available with Trip Pro

Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury. Traumatic brain injury (TBI) initiates a deleterious inflammatory response that exacerbates pathology and worsens outcome. This inflammatory response is partially mediated by a reduction in cAMP and a concomitant upregulation of cAMP-hydrolyzing phosphodiesterases (PDEs) acutely after TBI. The PDE4B subfamily, specifically PDE4B2, has been found to regulate cAMP in inflammatory cells, such as neutrophils (...) , macrophages and microglia. To determine if PDE4B regulates inflammation and subsequent pathology after TBI, adult male Sprague Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury (2 ± 0.2 atm) and were then treated with a PDE4B - selective inhibitor, A33, or vehicle for up to 3 days post-surgery. Treatment with A33 reduced markers of microglial activation and neutrophil infiltration at 3 and 24 hrs after TBI, respectively. A33 treatment also reduced cortical contusion

2017 PLoS ONE

139. Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment Full Text available with Trip Pro

Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment Pediatric heart failure (HF) patients have a suboptimal response to traditional HF medications, although phosphodiesterase-3 inhibition (PDE3i) has been used with greater success than in the adult HF population. We hypothesized that molecular alterations specific to children with HF and HF etiology may affect response to treatment.Adenylyl cyclase (AC (...) ) and phosphodiesterase (PDE) isoforms were quantified by means of quantitative real-time polymerase chain reaction in explanted myocardium from adults with dilated cardiomyopathy (DCM), children with DCM, and children with single-ventricle congenital heart disease of right ventricular morphology (SRV). AC and PDE expression profiles were uniquely regulated in each subject group and demonstratde distinct changes in response to chronic PDE3i. There was unique up-regulation of AC5 in adult DCM with PDE3i (fold change

2016 Journal of cardiac failure

140. Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. Full Text available with Trip Pro

Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. Prior investigations showed that increased levels of cyclic AMP down-regulate lung inflammatory changes, stimulating the interest in phosphodiesterase (PDE)4 as therapeutic target. Here, we described the synthesis, pharmacological profile and docking properties of a novel sulfonamide series (5 and 6a-k) designed as PDE4 inhibitors. Compounds were screened for their selectivity (...) of the putative interactions of LASSBio-448 revealed similar poses in the active site of PDE4A and PDE4C, but slight unlike orientations in PDE4B and PDE4D. LASSBio-448 (100 mg/kg, oral), 1 h before provocation, inhibited allergen-induced eosinophil accumulation in BAL fluid and lung tissue samples. Under an interventional approach, LASSBio-448 reversed ongoing lung eosinophilic infiltration, mucus exacerbation, peribronchiolar fibrosis and AHR by allergen provocation, in a mechanism clearly associated

2016 PLoS ONE

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>